14th June 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

More than 800 active integrations on the Ayushman Bharat Digital Mission

More than 800 integrations with Ayushman Bharat Digital Mission are currently active in the ABDM sandbox, enabling the provision of health services such as teleconsultations, diagnostic services, ambulance services, and lab tests, among others.

Pfizer laid off 200 "Field Force" employees in India, causing resentment

Pfizer Inc’s Indian arm immediately terminated over 200 of its ‘field force’ on June 6, citing’redundancy. ‘ This has sparked widespread anger among medical reps.

India concerned about references in TRIPS document, claiming pharma firms' profits take precedence over global good

India has expressed disappointment and concern about some references in the draught TRIPS document presented at the 12th ministerial meeting that do not include effective measures to combat pandemic challenges.

Novartis five-year Kymriah data show durable remission and long-term survival

Novartis announced long-term results of the ELIANA pivotal clinical trial of Kymriah, first CAR-T cell therapy approved, with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL), with a maximum survival follow-up of 5.9 years.

FDA extended BeiGene's Brukinsa review in blockbuster leukaemia arena

In chronic lymphocytic leukaemia, a key battleground for BTK inhibitors, AbbVie and Johnson & Johnson’s Imbruvica recently received a three-month reprieve before a potential clash with BeiGene’s rival med Brukinsa.

Glenmark shares fell to 52-week low following reports of USFDA inspection at Baddi plant

Glenmark Pharma’s stock fell almost 3% intraday on June 13 to a 52-week low of Rs 375, following allegations that the USFDA was inspecting the company’s Baddi plant. In October 2019, the USFDA issued a ‘Warning Letter’ to the Baddi plant.

Nuvectis Pharma Announces Positive Data for Group 4 Medulloblastoma Preclinical Model

Nuvectis Pharma stated that favourable evidence for NXP900 was presented on June 12th, 2022. “Aberrant SRC signalling has been established as a characteristic of Group 4 Medulloblastoma, ” said Chairman and Chief Executive Officer of Nuvectis.